Amendment No. 1

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, T7NkcMX4VS48Q9BoVDbhjDI72fOjom34/aN/f632rTJT6Qc19iF1Zx7kFFz2G7oo S7RAIACDvrDviXJ16bf9Iw== 0001193125-04-170178.txt : 20041012 0001193125-04-170178.hdr.sgml : 20041011 20041012161159 ACCESSION NUMBER: 0001193125-04-170178 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20041012 DATE AS OF CHANGE: 20041012 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: GERON CORPORATION CENTRAL INDEX KEY: 0000886744 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 752287752 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-49251 FILM NUMBER: 041074949 BUSINESS ADDRESS: STREET 1: 230 CONSTITUTION DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 6504737700 MAIL ADDRESS: STREET 1: 200 CONSTITUTION DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MERIX BIOSCIENCE INC CENTRAL INDEX KEY: 0001105533 IRS NUMBER: 562110007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 4233 TECHNOLOGY DR CITY: DURHAM STATE: NC ZIP: 27704 BUSINESS PHONE: 9192876300 MAIL ADDRESS: STREET 1: 4233 TECHNOLOGY DR CITY: DURHAM STATE: NC ZIP: 27704 SC 13G/A 1 dsc13ga.htm AMENDMENT NO. 1 Amendment No. 1

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Geron Corporation

(Name of Issuer)

Common Stock, Par Value $0.001 Per Share

(Title of Class of Securities)

374163103

(CUSIP Number)

October 7, 2004

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

x Rule 13d-1(c)

¨ Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 374163103		SCHEDULE 13G


1.		Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Merix Bioscience, Inc.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.		SEC USE ONLY
4.		Citizenship or Place of Organization Delaware, United States

Number of

Beneficially

Owned by

Each

Reporting

Person

With:

5. Sole Voting Power

2,681,800 (See Item 4)

6. Shared Voting Power

7. Sole Dispositive Power

2,681,800 (See Item 4)

8. Shared Dispositive Power


9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,681,800
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)	¨
11.	Percent of Class Represented by Amount in Row (9) 5.9% (See Item 4)
12.	Type of Reporting Person CO

Item 1.

(a)

Name of Issuer

Geron Corporation

(b)

Address of Issuer’s Principal Executive Offices

230 Constitution Drive

Menlo Park, California 94025

Item 2.

(a)

Name of Person Filing

Merix Bioscience, Inc.

(b)

Address of Principal Business Office or, if none, Residence

4233 Technology Drive

Durham, NC 27704

(c)

Citizenship

State of Delaware, United States

(d)

Title of Class of Securities

Common Stock

(e)

CUSIP Number

374163103

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

(e)

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

Group, in accordance with §240.13d-1(b)(1)(ii)(J).

If this statement is filed pursuant to Rule 13d-1(c), check this box



Item 4.	Ownership.

	(a)	Amount beneficially owned:

		2,681,800 shares of Common Stock

	(b)	Percent of class:

		5.9%¹

	(c)	Number of shares as to which the person has:

		(i)	Sole power to vote or to direct the vote

			2,681,800

		(ii)	Shared power to vote or to direct the vote

			0

		(iii)	Sole power to dispose or to direct the disposition of

			2,681,800

		(iv)	Shared power to dispose or to direct the disposition of

			0

Item 5.	Ownership of Five Percent or Less of a Class

	Inapplicable.

Item 6.	Ownership of More than Five Percent on Behalf of Another Person

	Inapplicable.

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

	Inapplicable.

Item 8.	Identification and Classification of Members of the Group

	Inapplicable.

Item 9.	Notice of Dissolution of Group

	Inapplicable.

Item 10.	Certification

	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Based on 45,417,480 shares of Common Stock issued and outstanding as of July 27, 2004 as reported by the Issuer on its most recent filing on Form 10-Q.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 11, 2004


Merix Bioscience, Inc.

By:		/s/ Timothy Trost
		Timothy Trost, Chief Financial Officer

-----END PRIVACY-ENHANCED MESSAGE-----